First, TMB, as a surrogate measure for tumor immunogenicity, predicts responses less reliably in patients treated with combined anti-CTLA-4/PD-1 blockade than with anti-PD-1 monotherapy [18, 19]. Here, CTLA4 is linked to neoplasm.